Virometix, a Swiss developer of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, has raised CHF 7.5 million in Series B financing. The investors were not named.
Source: Press Release
Virometix inks Series B
Virometix, a developer of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, has raised CHF 7.5 million in Series B financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: